Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Group parent-child interaction therapy: A randomized control trial for the treatment of conduct problems in young children.

Niec LN, Barnett ML, Prewett MS, Shanley Chatham JR.

J Consult Clin Psychol. 2016 Aug;84(8):682-698. doi: 10.1037/a0040218. Epub 2016 Mar 28.

2.

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor.

Forest A, Amatulli M, Ludwig DL, Damoci CB, Wang Y, Burns CA, Donoho GP, Zanella N, Fiebig HH, Prewett MC, Surguladze D, DeLigio JT, Houghton PJ, Smith MA, Novosiadly R.

Mol Cancer Res. 2015 Dec;13(12):1615-26. doi: 10.1158/1541-7786.MCR-15-0279. Epub 2015 Aug 11.

3.

A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.

Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL.

MAbs. 2015;7(5):931-45. doi: 10.1080/19420862.2015.1055442.

4.

CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.

Mendelsohn J, Prewett M, Rockwell P, Goldstein NI.

Clin Cancer Res. 2015 Jan 15;21(2):227-9. doi: 10.1158/1078-0432.CCR-14-2491.

5.

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.

Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H.

Cancer Biol Ther. 2014 Sep;15(9):1208-18. doi: 10.4161/cbt.29523. Epub 2014 Jun 12.

6.

Teamwork in the trauma room evaluation of a multimodal team training program.

Peckler B, Prewett MS, Campbell T, Brannick M.

J Emerg Trauma Shock. 2012 Jan;5(1):23-7. doi: 10.4103/0974-2700.93106.

7.

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.

Samakoglu S, Deevi DS, Li H, Wang S, Murphy M, Bao C, Bassi R, Prewett M, Tonra JR.

Cancer Genomics Proteomics. 2012 Mar-Apr;9(2):77-92.

PMID:
22399498
8.

A systematic review of the reliability of objective structured clinical examination scores.

Brannick MT, Erol-Korkmaz HT, Prewett M.

Med Educ. 2011 Dec;45(12):1181-9. doi: 10.1111/j.1365-2923.2011.04075.x. Epub 2011 Oct 11. Review.

PMID:
21988659
9.

Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

Prewett M, Bassi R, Paz K, Amatulli M, Deevi D, Li H, Wang S, Witte L, Samakoglu S, Tonra JR.

Anticancer Res. 2011 Jun;31(6):2149-60.

PMID:
21737635
10.

Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.

Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.

Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9.

11.
12.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z.

Neoplasia. 2009 Jun;11(6):594-604.

13.

In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.

Tonra JR, Prewett M, Corcoran E, Hicklin DJ, Zhu Z.

Methods Mol Biol. 2009;525:545-57, xv. doi: 10.1007/978-1-59745-554-1_30.

PMID:
19252838
14.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.

Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X.

Int J Oncol. 2009 Jan;34(1):25-32.

PMID:
19082474
15.

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.

Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR.

Clin Cancer Res. 2007 Dec 15;13(24):7432-40.

16.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, Jimenez X, Iacolina M, Bassi R, Zhou K, Balderes P, Mangalampalli VR, Loizos N, Ludwig DL, Zhu Z.

Biochem Biophys Res Commun. 2007 Jun 15;357(4):1142-7. Epub 2007 Apr 19.

PMID:
17462601
17.

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS.

Cancer Res. 2006 Sep 15;66(18):9162-70.

18.

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z.

J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9.

19.

Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.

Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D, Pereira DS, Jimenez X, Fox F, Saxena B, Zhou Q, Ma Y, Kang X, Patel D, Barry M, Kussie P, Zhu Z, Russell DA, Petersen WL, Jury TP, Gaitan-Gaitan F, Moran DL, Delannay X, Storrs BS, Tou J, Zupec ME, Gustafson KS, McIntyre J, Tarnowski SJ, Bohlen P.

Hum Antibodies. 2004;13(3):81-90. Erratum in: Hum Antibodies. 2009;18(4):157. Dosage error in article text.

PMID:
15598988
20.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL.

Cancer Res. 2003 Dec 15;63(24):8912-21.

21.
22.

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.

Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ.

Cancer. 2000 Jul 1;89(1):74-82.

PMID:
10897003
23.

Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.

Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D.

Cancer Immunol Immunother. 2000 Jun;49(3):123-32.

PMID:
10881691
24.

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ.

Cancer Res. 1999 Oct 15;59(20):5209-18.

25.

Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.

Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ.

Clin Cancer Res. 1998 Dec;4(12):2957-66.

26.

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.

Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI.

J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):419-27.

PMID:
9041461
27.
28.

Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733.

Maruyama H, Benden A, Li W, Zaloudik J, Koido T, Taupin JL, Acres B, Somasundaram R, Prewett M, Herlyn D.

Int J Cancer. 1996 Feb 8;65(4):547-53.

29.

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J.

Clin Cancer Res. 1995 Nov;1(11):1311-8.

30.

Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells.

Su ZZ, Lin J, Prewett M, Goldstein NI, Fisher PB.

Anticancer Res. 1995 Sep-Oct;15(5B):1841-8.

PMID:
8572568
31.

Neuropsychiatric disorders, myoclonus, and dystonia in calcification of basal ganglia pathways.

Lauterbach EC, Spears TE, Prewett MJ, Price ST, Jackson JG, Kirsh AD.

Biol Psychiatry. 1994 Mar 1;35(5):345-51.

PMID:
8011802
32.

Polyclonal antiidiotypic antibodies mimicking gp120 of HIV-1.

Sperlagh M, Hoxie J, Maruyama H, Stefano K, Gonzales-Scarano F, Prewett M, Liang S, Matsushita S, Herlyn D.

Viral Immunol. 1994;7(2):61-9.

PMID:
7531443
33.

Monoclonal anti-idiotypic antibodies that mimic the epitope on gp120 defined by anti-HIV-1 monoclonal antibody 0.5 beta.

Sperlagh M, Stefano K, Gonzalez-Scarano F, Liang S, Hoxie J, Maruyama H, Prewett M, Matsushita S, Herlyn D.

AIDS. 1993 Dec;7(12):1553-9.

PMID:
7506914
34.

Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.

Bender H, Takahashi H, Adachi K, Belser P, Liang SH, Prewett M, Schrappe M, Sutter A, Rodeck U, Herlyn D.

Cancer Res. 1992 Jan 1;52(1):121-6.

35.

Anti-idiotypic antibodies against anti-CD4 antibodies MT151 and OKT4A.

Liang SH, Rieber P, Prewett M, Riethm├╝ller G, Pletcher C, Hoxie J, Koprowski H, Herlyn D.

Viral Immunol. 1991 Summer;4(2):83-90.

PMID:
1722100
36.

Dopamine-responsive dysnomia?

Lauterbach EC, Spears TE, Prewett MJ.

J Neuropsychiatry Clin Neurosci. 1990 Summer;2(3):353-4. No abstract available.

PMID:
2136096
37.

Attribution of causality by children with alcoholic parents.

Prewett MJ, Spence R, Chaknis M.

Int J Addict. 1981 Feb;16(2):367-70. No abstract available.

PMID:
7275387
38.

Dietary changes associated with electroconvulsive shock.

Milner JS, Prewett MJ.

Behav Neural Biol. 1979 Aug;26(4):502-7. No abstract available.

PMID:
496789
39.

Electroconvulsive shock and the estrous cycle in the rat.

Milner JS, Gilbert LF, Prewett MJ.

Behav Biol. 1978 Oct;24(2):279-83. No abstract available.

PMID:
570033
40.

Effects of electroconvulsive shock on food and water intake in the rat.

Prewett MJ, Milner JS.

Physiol Behav. 1977 Aug;19(2):341-3.

PMID:
607248
41.

Alpha activity suppression and enhancement as a function of feedback and instructions.

Prewett MJ, Adams HE.

Psychophysiology. 1976 Jul;13(4):307-10. No abstract available.

PMID:
951471
42.

Factors in the modification by isolation of electroconvulsive shock-produced retrograde amnesia in the rat.

Calhoun KS, Prewett MJ, Peters RD, Adams HE.

J Comp Physiol Psychol. 1975 Jan;88(1):373-7.

PMID:
1168207

Supplemental Content

Loading ...
Support Center